ECHO-310: A phase 3, randomized trial of epacadostat plus nivolumab plus chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

被引：1
|
作者：
Cohen, Ezra E. W.
Mehra, Ranee
Psyrri, Amanda
Bauman, Julie E.
Schaub, Richard
Zhou, Li
Li, Li
Jayaprakash, Vijayvel
Guigay, Joel
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Johns Hopkins Med Ctr, Baltimore, MD USA
[3] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece
[4] Univ Arizona, Coll Med, Tucson, AZ USA
[5] Incyte Corp, Wilmington, DE USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] Ctr Antoine Lacassagne, Nice, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS6092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6092
引用
收藏
页数：2
相关论文
共 50 条
  • [31] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [32] RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine plus cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
    Yang, Y.
    Pan, J.
    Wang, H.
    Qu, S.
    Chen, N.
    Chen, X.
    Sun, Y.
    He, X.
    Hu, C.
    Lin, L.
    Yu, Q.
    Wang, S.
    Wang, G.
    Lei, F.
    Wen, J.
    Yang, K.
    Lin, Z.
    Wu, Y.
    Fang, W.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1430 - S1430
  • [33] Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
    Assenat, Eric
    Desseigne, Francoise
    Thezenas, Simon
    Viret, Frederic
    Mineur, Laurent
    Kramar, Andrew
    Samalin, Emmanuelle
    Portales, Fabienne
    Bibeau, Frederic
    Crapez-Lopez, Evelyne
    Bleuse, Jean Pierre
    Ychou, Marc
    ONCOLOGIST, 2011, 16 (11): : 1557 - 1564
  • [34] Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)
    Lopez, Rafael
    Mendez Mendez, Carlos
    Jorge Fernandez, Monica
    Romero Reinoso, Carlos
    Quintero Aldana, Guillermo
    Salgado Fernandez, Mercedes
    De La Camara Gomez, Juan
    Reboredo Lopez, Margarita
    Ramos Vazquez, Manuel
    Candamio Folgar, Sonia
    ANTICANCER RESEARCH, 2013, 33 (02) : 717 - 723
  • [35] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
  • [36] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    F Cappuzzo
    F Mazzoni
    A Gennari
    S Donati
    B Salvadori
    C Orlandini
    G L Cetto
    A Molino
    E Galligioni
    M Mansutti
    S Tumolo
    A Lucentini
    F Valduga
    S Bartolini
    L Crinò
    P F Conte
    British Journal of Cancer, 2004, 90 : 31 - 35
  • [37] First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
    Zhang, L.
    Huang, Y.
    Yang, Y.
    Ma, S.
    Lin, X.
    Lin, L.
    Zhou, T.
    Deng, Y.
    Zhang, C.
    Ding, X.
    Wang, S.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck The Phase 2 CheckMate 714 Randomized Clinical Trial
    Harrington, Kevin J.
    Ferris, Robert L.
    Gillison, Maura
    Tahara, Makoto
    Argiris, Athanasios
    Fayette, Jerome
    Schenker, Michael
    Bratland, Ase
    Walker, John W. T.
    Grell, Peter
    Even, Caroline
    Chung, Christine H.
    Redman, Rebecca
    Coutte, Alexandre
    Salas, Sebastien
    Grant, Cliona
    de Azevedo, Sergio
    Soulieres, Denis
    Hansen, Aaron R.
    Wei, Li
    Khan, Tariq Aziz
    Miller-Moslin, Karen
    Roberts, Mustimbo
    Haddad, Robert
    JAMA ONCOLOGY, 2023, 9 (06) : 779 - 789
  • [39] First-Line Nivolumab plus Ipilimumab plus Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update
    Carbone, D. P.
    Paz-Ares, L. G.
    Ciuleanu, T. E.
    Cobo-Dols, M.
    Bennouna, J.
    Cheng, Y.
    Mizutani, H.
    Lingua, A.
    Reyes, F.
    Reinmuth, N.
    Menezes, J.
    Jassem, J.
    Protsenko, S.
    Feeney, K.
    Jimenez, E. De la Mora
    Lu, S.
    John, T.
    Zhang, X.
    Hu, N.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E2 - E2
  • [40] First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
    Wan, XiaoMin
    Zhang, YuCong
    Tan, ChongQing
    Zeng, XiaoHui
    Peng, LiuBao
    JAMA ONCOLOGY, 2019, 5 (04) : 491 - 496
12345